ERBB2 and breast carcinoma: From Annex 3, all 5 participants with HER2-enriched breast cancer had c.34311 as the predominant variant location, 4 participants with triple-negative breast cancer had c.34311 as the predominant variant location, 3 participants with normal-like breast cancer had c.34311 as the predominant variant location and 2 participants with luminal B breast cancer had c.34311 as the predominant variant location.